原发性血脂代谢紊乱患者63 例随机分为脂必妥治疗组(32 例) 和辛伐他汀对照组(31 例) 。脂必妥(0-96g/d) 治疗6 周使TC、LDLC、TG 分别下降32-5 % 、39-2 % 和21 % ,HDLC 升高5-7 % ,辛伐他汀(10 mg/d) 则分别为38-7 % 、42-7 % 、30-2 % 和8-1 % 。脂必妥调节TC、TG、HDLC、TCHDL/HDL 紊乱的总有效率分别为90-6 % 、59-4 % 、56-3 % 和93-8 % ,而对照组分别为90-3 % 、67-3 % 、41-9 % 、93-5 % 。表明每日口服0-96g 脂必妥胶囊调节血脂代谢紊乱的效果与10 mg 辛伐他汀效果基本相同 Sixty-three patients with primary dyslipidemia were randomly divided into the treatment group (32 cases) and the simvastatin control group (31 cases). Lipid (0-96g / d) for 6 weeks to TC, LDL C, TG decreased 32-5%, 39-2% and 21%, HDL C elevated 5-7%, simvastatin ( 10 mg / d) were 38-7%, 42-7%, 30-2% and 8-1%, respectively. The total effective rate of lipid for regulating TC, TG, HDL-C, TC-HDL / HDL disorders was 90-6%, 59-4%, 56-3% and 93-8%, respectively, while the control group was 90 -3%, 67-3%, 41-9%, 93-5%. The results showed that oral administration of 0-96g lipidophil capsule dyslipidemia effect and 10 mg simvastatin effect is basically the same